Cleerly ISCHEMIA vs ASSURE Wearable ECG
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a comprehensive, non-invasive assessment of coronary artery disease, including detailed plaque characterization and the likelihood of vessel-level ischemia, derived from a CCTA scan. This tool is ideal for initial diagnosis, risk stratification, and guiding personalized treatment plans by providing a deep understanding of coronary anatomy and functional significance.
View Cleerly ISCHEMIA →Choose ASSURE Wearable ECG if…
Choose ASSURE Wearable ECG if continuous, long-term heart rate monitoring and arrhythmia detection are essential for at-risk cardiac patients in an outpatient or remote setting. This wearable device is best suited for capturing transient cardiac events, providing ongoing patient surveillance, and enabling clinicians to review physiologic trend data through a remote patient data platform.
View ASSURE Wearable ECG →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | ASSURE Wearable ECG |
|---|---|---|
| Deployment | Web-based solution | The ASSURE system is intended for use by a patient during their normal daily activities primarily in the home or community setting, but also hospitals, medical clinics, healthcare facilities and transport. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ASSURE Wearable ECGThe ASSURE Wearable ECG prioritizes patient comfort and ease of use with its SensorFit Garment and mobile application, making it highly usable for the patient, who is the primary operator of the device. While Cleerly ISCHEMIA offers an interactive web platform for clinicians, the patient-centric design of Tool B gives it an edge in overall usability for its target user.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA offers a more direct and definitive diagnostic clinical value by providing detailed, quantitative insights into coronary artery disease, including non-invasive FFR estimation and comprehensive plaque characterization, which can directly guide treatment planning and revascularization decisions. While Tool B provides valuable continuous monitoring, Tool A's diagnostic capabilities for CAD have a higher immediate impact on specific treatment pathways.
Pricing & Value
TieBoth tools lack transparent public pricing, making a direct comparison of value difficult. While Tool A provides a slight detail about the Cleerly Proxy being included, this is insufficient to declare a clear winner in terms of overall pricing and value.
Enterprise Readiness
Cleerly ISCHEMIACleerly ISCHEMIA demonstrates stronger enterprise readiness through its explicit mention of integration with PowerScribe via API and data transfer via VPN or virtual appliance, indicating a design for seamless integration into existing clinical IT infrastructure and radiology workflows. While Tool B is also enterprise-ready with its cloud platform, it doesn't detail specific integration points with broader hospital systems.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA exhibits a higher degree of innovation by leveraging advanced AI to derive complex functional and pathological insights, such as non-invasive fractional flow reserve (FFR) estimation and detailed plaque characterization, directly from CCTA scans. This pushes the boundaries of non-invasive cardiac diagnostics beyond traditional imaging analysis.
Support & Docs
ASSURE Wearable ECGKestra Medical Technologies provides more explicit and comprehensive support and documentation for its ASSURE Wearable ECG, including a 24/7 helpline, dedicated patient handbooks and user manuals, and in-person training for patients by service representatives. While Cleerly implies support through compliance standards, Tool B's offerings are more clearly articulated and robust.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | ASSURE Wearable ECG |
|---|---|---|
| Tool Name | Cleerly ISCHEMIA | ASSURE Wearable ECG |
| Company | Cleerly | Kestra Medical Technologies |
| Description | Cleerly ISCHEMIA is an FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | Kestra Medical Technologies offers the ASSURE Wearable ECG, a non-therapeutic device for continuous heart rate monitoring and data collection, integrated into their digital healthcare platform for at-risk cardiac patients. |
| Primary Category | Cardiology AI | Cardiology AI |
| Key Features (Examples) | AI-enabled CCTA analysis, Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination | Wearable ECG device for continuous heart rate monitoring, SensorFit Garment with non-adhesive, embedded, and cushioned ECG sensors, ASSURE Detection Algorithm with Quad Channel Processingu2122 |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and ASSURE Wearable ECG.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or ASSURE Wearable ECG
Backers
Who funded each tool's parent company.